摘要
目的了解淋巴瘤患者血清中抗磷脂抗体（APL）的阳性率及水平，探讨抗磷脂抗体淋巴瘤患者中的临床和免疫学意义。方法应用ELISA法检测129例淋巴瘤、46例系统性红斑狼疮（SLE）、38例类风湿关节炎（RA）、24例原发性干燥综合征（pSS）及58名健康对照的血清中的抗心磷脂抗体IgG／M／A和抗B：糖蛋白I抗体IgG／M／A，分析其与淋巴瘤患者一般情况、临床特点、免疫学表型及血栓事件的关系。结果（1）抗磷脂抗体在淋巴瘤患者血清中的阳性率为40．3％（52／129），其中抗心磷脂抗体阳性率11．6％（15／129），抗p2糖蛋白I抗体阳性率32．6％（42／129）。抗心磷脂抗体及抗β2糖蛋白I抗体在淋巴瘤患者血清中的水平及阳性率均明显高于健康对照组（P〈0．05），而与SLE、RA、pSS组的抗体水平相仿（P〉0．05）。（2）T或NK／T细胞淋巴瘤中抗磷脂抗体阳性率明显高于B细胞淋巴瘤（P〈0．05）。（3）抗磷脂抗体阳性与阴性的淋巴瘤患者中血栓事件的发生率差异无统计学意义。（4）抗磷脂抗体阳性淋巴瘤患者的无事件生存时间短于抗磷脂抗体阴性者。结论抗磷脂抗体在淋巴瘤患者血清中的阳性率及抗体水平均较健康人群明显升高，与SLE等自身免疫病患者无明显差别。抗磷脂抗体多见于T或NK／T细胞来源的非霍奇金淋巴瘤。抗磷脂抗体可能与淋巴瘤患者的无事件生存时间有关。
Objective To explore the prevalence, clinical and prognostic significance of anticardiolipin （aCL） IgG/M/A antibodies and anti-β2-glycoprotein I （2-GPI） IgG/M/A antibodies in patients with lymphoma. Methods ACL IgG/M/A antibodies and anti-β2-GPI IgG/M/A antibodies were determined by enzyme-linked immunosorbent assay （ELISA） in 129 lymphoma patients, 46 SLE patients, 38 rheumatoid arthritis （RA） patients, 24 primary Sjogren＇s syndrome （pSS） patients and 58 healthy controls. Laboratory and clinical features （thrombosis, event-free-survival time, etc. ） were analyzed retrospectively from the clinical database. Results （ 1 ） Elevated APL level was found in 52/129 lymphoma patients （40.3%） ： aCL IgG/M/A antibodies in 11.6% （15/129） and anti-β2-GPI IgG/M/A antibodies in 32.6% （42/129） of lymphoma patients. There were significant differences between the prevalence and level of APL in lymphoma patients and healthy controls. But no difference was found between the lymphoma patients and SLE, RA or pSS patients. （2） APL was correlated with lymphoma dervied from T or NK/T cells （ P 〈 0.05 ）. （3） No difference was found between the incidence of thrombosis in lymphoma patients with or without APL. （4） A strong negative correlation was found between the elevated APL and the eventfree survival. Conclusion APL is elevated in 40.3% of lymphoma patients. And it is significantly higher than that in healthy controls and similar with that in SLE, RA or pSS patients. APL is correlated with lymphoma cell origin and shortened event-free survival.
出处
《中华医学杂志》
CAS
CSCD
北大核心
2011年第37期2607-2610,共4页
National Medical Journal of China
基金
基金项目：国家“十一五”科技支撑计划课题（2008BA159802）
北京自然科学基金（7072085）
关键词
抗体
抗磷脂
抗体
抗心磷脂
非霍奇金淋巴瘤
霍奇金病
Antibodies, antiphospholipid
Antibodies, anticardiolipin
Lymphoma,Non-Hodgkin
Hodgkin disease
